



A Pfizer Company

# SAFETY DATA SHEET

Revision date: 24-Mar-2017

Version: 1.0

Page 1 of 11

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Clindamycin phosphate injection, solution (Hospira, Inc.)

**Trade Name:** Not established

**Chemical Family:** Mixture

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used as antibiotic agent

### Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Hospira UK Limited  
Horizon  
Honey Lane  
Hurley  
Maidenhead, SL6 6RJ  
United Kingdom

### Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

### Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Skin Corrosion/Irritation: Category 3

Serious Eye Damage/Eye Irritation: Category 2A

Skin Sensitization: Category 1

### Label Elements

**Signal Word:** Warning

**Hazard Statements:** H319 - Causes serious eye irritation

H316 - Causes mild skin irritation

H317 - May cause an allergic skin reaction

## SAFETY DATA SHEET

**Material Name: Clindamycin phosphate injection, solution**  
**(Hospira, Inc.)**  
**Revision date: 24-Mar-2017**

**Page 2 of 11**

**Version: 1.0**

**Precautionary Statements:**

- P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
- P264 - Wash hands thoroughly after handling
- P272 - Contaminated work clothing must not be allowed out of the workplace
- P280 - Wear protective gloves/protective clothing/eye protection/face protection
- P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
- P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing
- P337 + P313 - If eye irritation persists: Get medical advice/attention
- P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
- P321 - Specific treatment (see supplemental first aid instructions on this label)
- P363 - Wash contaminated clothing before reuse
- P501 - Dispose of contents/container in accordance with all local and national regulations



**Other Hazards**

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

**Note:**

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

**Hazardous**

| Ingredient            | CAS Number | EU EINECS/ELINCS List | GHS Classification   | %    |
|-----------------------|------------|-----------------------|--|------|
| Clindamycin Phosphate | 24729-96-2 | 246-433-0             | Acute Tox.4 (H302)<br>Eye Irrit.2A (H319)<br>Skin Irrit.3 (H316)<br>Skin Sens.1 (H317) | 15   |
| Benzyl Alcohol        | 100-51-6   | 202-859-9             | Acute Tox.4 (H302)<br>Acute Tox.4 (H332)   | <1.0 |
| HYDROCHLORIC ACID     | 7647-01-0  | 231-595-7             | Skin Corr.1B (H314)<br>STOT SE 3 (H335)  | **   |
| Sodium hydroxide      | 1310-73-2  | 215-185-5             | Skin Corr.1A (H314)  | **   |

| Ingredient          | CAS Number | EU EINECS/ELINCS List | GHS Classification | % |
|---------------------|------------|-----------------------|--------------------|---|
| Water for Injection | 7732-18-5  | 231-791-2             | Not Listed         | * |

## SAFETY DATA SHEET

Material Name: Clindamycin phosphate injection, solution  
(Hospira, Inc.)  
Revision date: 24-Mar-2017

Page 3 of 11

Version: 1.0

**Additional Information:** \* Proprietary  
\*\* to adjust pH  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

#### Description of First Aid Measures

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. If irritation occurs or persists, get medical attention.

**Skin Contact:** Remove contaminated clothing and wash exposed area with soap and water. Obtain medical assistance if irritation occurs.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

#### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:** None known

#### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** None

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

#### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

#### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

#### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

## SAFETY DATA SHEET

Material Name: Clindamycin phosphate injection, solution  
(Hospira, Inc.)  
Revision date: 24-Mar-2017

Page 4 of 11

Version: 1.0

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

#### Precautions for Safe Handling

Minimize generating airborne mists and vapors. Avoid breathing mist or aerosols. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

#### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.  
**Specific end use(s):** Pharmaceutical drug product

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Clindamycin Phosphate

Pfizer OEL TWA-8 Hr: 100µg/m<sup>3</sup>

#### Benzyl Alcohol

Bulgaria OEL - TWA 5.0 mg/m<sup>3</sup>  
Czech Republic OEL - TWA 40 mg/m<sup>3</sup>  
Finland OEL - TWA 10 ppm  
45 mg/m<sup>3</sup>  
Latvia OEL - TWA 5 mg/m<sup>3</sup>  
Lithuania OEL - TWA 5 mg/m<sup>3</sup>  
Poland OEL - TWA 240 mg/m<sup>3</sup>

#### HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit: 2 ppm  
Australia PEAK 5 ppm  
7.5 mg/m<sup>3</sup>  
Austria OEL - MAKs 5 ppm  
8 mg/m<sup>3</sup>  
Belgium OEL - TWA 5 ppm  
8 mg/m<sup>3</sup>  
Bulgaria OEL - TWA 5 ppm  
8.0 mg/m<sup>3</sup>  
Cyprus OEL - TWA 5 ppm  
8 mg/m<sup>3</sup>  
Czech Republic OEL - TWA 8 mg/m<sup>3</sup>  
Estonia OEL - TWA 5 ppm  
8 mg/m<sup>3</sup>  
Germany - TRGS 900 - TWAs 2 ppm  
3 mg/m<sup>3</sup>  
Germany (DFG) - MAK 2 ppm  
3.0 mg/m<sup>3</sup>

## SAFETY DATA SHEET

Material Name: Clindamycin phosphate injection, solution  
 (Hospira, Inc.)  
 Revision date: 24-Mar-2017

Page 5 of 11

Version: 1.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

|                                |                                |
|--------------------------------|--------------------------------|
| Greece OEL - TWA               | 5 ppm<br>7 mg/m <sup>3</sup>   |
| Hungary OEL - TWA              | 8 mg/m <sup>3</sup>            |
| Ireland OEL - TWAs             | 5 ppm<br>8 mg/m <sup>3</sup>   |
| Italy OEL - TWA                | 5 ppm<br>8 mg/m <sup>3</sup>   |
| Japan - OELs - Ceilings        | 2 ppm<br>3.0 mg/m <sup>3</sup> |
| Latvia OEL - TWA               | 5 ppm<br>8 mg/m <sup>3</sup>   |
| Lithuania OEL - TWA            | 5 ppm<br>8 mg/m <sup>3</sup>   |
| Luxembourg OEL - TWA           | 5 ppm<br>8 mg/m <sup>3</sup>   |
| Malta OEL - TWA                | 5 ppm<br>8 mg/m <sup>3</sup>   |
| Netherlands OEL - TWA          | 8 mg/m <sup>3</sup>            |
| Poland OEL - TWA               | 5 mg/m <sup>3</sup>            |
| Portugal OEL - TWA             | 5 ppm<br>8 mg/m <sup>3</sup>   |
| Romania OEL - TWA              | 5 ppm<br>8 mg/m <sup>3</sup>   |
| Slovakia OEL - TWA             | 5 ppm<br>8.0 mg/m <sup>3</sup> |
| Slovenia OEL - TWA             | 5 ppm<br>8 mg/m <sup>3</sup>   |
| Spain OEL - TWA                | 5 ppm<br>7.6 mg/m <sup>3</sup> |
| Switzerland OEL - TWAs         | 2 ppm<br>3.0 mg/m <sup>3</sup> |
| Vietnam OEL - TWAs             | 5 mg/m <sup>3</sup>            |
| <b>Sodium hydroxide</b>        |                                |
| ACGIH Ceiling Threshold Limit: | 2 mg/m <sup>3</sup>            |
| Australia PEAK                 | 2 mg/m <sup>3</sup>            |
| Austria OEL - MAKs             | 2 mg/m <sup>3</sup>            |
| Bulgaria OEL - TWA             | 2.0 mg/m <sup>3</sup>          |
| Czech Republic OEL - TWA       | 1 mg/m <sup>3</sup>            |
| Estonia OEL - TWA              | 1 mg/m <sup>3</sup>            |
| France OEL - TWA               | 2 mg/m <sup>3</sup>            |
| Greece OEL - TWA               | 2 mg/m <sup>3</sup>            |
| Hungary OEL - TWA              | 2 mg/m <sup>3</sup>            |
| Japan - OELs - Ceilings        | 2 mg/m <sup>3</sup>            |
| Latvia OEL - TWA               | 0.5 mg/m <sup>3</sup>          |
| OSHA - Final PELs - TWAs:      | 2 mg/m <sup>3</sup>            |
| Poland OEL - TWA               | 0.5 mg/m <sup>3</sup>          |
| Slovakia OEL - TWA             | 2 mg/m <sup>3</sup>            |
| Slovenia OEL - TWA             | 2 mg/m <sup>3</sup>            |
| Sweden OEL - TWAs              | 1 mg/m <sup>3</sup>            |
| Switzerland OEL - TWAs         | 2 mg/m <sup>3</sup>            |

Exposure Controls

## SAFETY DATA SHEET

Material Name: Clindamycin phosphate injection, solution  
(Hospira, Inc.)  
Revision date: 24-Mar-2017

Page 6 of 11

Version: 1.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

|                                       |   |
|---------------------------------------|---|
| <b>Engineering Controls:</b>          | Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.  |
| <b>Personal Protective Equipment:</b> | Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. |
| <b>Hands:</b>                         | Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)  |
| <b>Eyes:</b>                          | Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)   |
| <b>Skin:</b>                          | Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)   |
| <b>Respiratory protection:</b>        | Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)                          |

### 9. PHYSICAL AND CHEMICAL PROPERTIES

|   |                    |                          |                    |
|---|--------------------|--------------------------|--------------------|
| <b>Physical State:</b>                                      | Solution           | <b>Color:</b>            | Clear, colorless   |
| <b>Odor:</b>  | No data available. | <b>Odor Threshold:</b>   | No data available. |
| <b>Molecular Formula:</b>                                   | Mixture            | <b>Molecular Weight:</b> | Mixture            |
| <b>Solvent Solubility:</b>                                  | No data available  |                          |                    |
| <b>Water Solubility:</b>                                    | No data available  |                          |                    |
| <b>pH:</b>  | No data available. |                          |                    |
| <b>Melting/Freezing Point (°C):</b>                         | No data available  |                          |                    |
| <b>Boiling Point (°C):</b>                                  | No data available. |                          |                    |
| <b>Partition Coefficient: (Method, pH, Endpoint, Value)</b> |                    |                          |                    |
| <b>Clindamycin Phosphate</b>                                |                    |                          |                    |
| No data available   |                    |                          |                    |
| <b>Water for Injection</b>                                  |                    |                          |                    |
| No data available   |                    |                          |                    |
| <b>Benzyl Alcohol</b>                                       |                    |                          |                    |
| No data available   |                    |                          |                    |
| <b>Edetate disodium</b>                                     |                    |                          |                    |
| No data available   |                    |                          |                    |
| <b>Sodium hydroxide</b>                                     |                    |                          |                    |
| No data available   |                    |                          |                    |
| <b>HYDROCHLORIC ACID</b>                                    |                    |                          |                    |
| No data available   |                    |                          |                    |
| <b>Decomposition Temperature (°C):</b>                      | No data available. |                          |                    |
| <b>Evaporation Rate (Gram/s):</b>                           | No data available  |                          |                    |
| <b>Vapor Pressure (kPa):</b>                                | No data available  |                          |                    |
| <b>Vapor Density (g/ml):</b>                                | No data available  |                          |                    |
| <b>Relative Density:</b>                                    | No data available  |                          |                    |
| <b>Viscosity:</b>   | No data available  |                          |                    |

## SAFETY DATA SHEET

Material Name: Clindamycin phosphate injection, solution  
(Hospira, Inc.)  
Revision date: 24-Mar-2017

Page 7 of 11

Version: 1.0

### Flammability:

|  |                   |
|--|-------------------|
| Autoignition Temperature (Solid) (°C):       | No data available |
| Flammability (Solids):                       | No data available |
| Flash Point (Liquid) (°C):                   | No data available |
| Upper Explosive Limits (Liquid) (% by Vol.): | No data available |
| Lower Explosive Limits (Liquid) (% by Vol.): | No data available |

## 10. STABILITY AND REACTIVITY

|                                    |  |
|------------------------------------|--|
| Reactivity:                        | No data available  |
| Chemical Stability:                | Stable under normal conditions of use.                             |
| Possibility of Hazardous Reactions |  |
| Oxidizing Properties:              | No data available  |
| Conditions to Avoid:               | Fine particles (such as dust and mists) may fuel fires/explosions. |
| Incompatible Materials:            | As a precautionary measure, keep away from strong oxidizers        |
| Hazardous Decomposition Products:  | No data available  |

## 11. TOXICOLOGICAL INFORMATION

### Information on Toxicological Effects

|                         |   |
|-------------------------|---|
| General Information:    | The information included in this section describes the potential hazards of the individual ingredients.   |
| Short Term:             | Active ingredient may be harmful if swallowed. May cause eye irritation May cause skin irritation. (based on components)  |
| Known Clinical Effects: | Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused sore throat, fever, gastrointestinal disturbances, abnormal liver function tests, kidney dysfunction. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur. |

### Acute Toxicity: (Species, Route, End Point, Dose)

#### Clindamycin Phosphate

|       |                 |       |            |
|-------|-----------------|-------|------------|
| Rat   | Oral            | LD 50 | 1832 mg/kg |
| Rat   | Para-periosteal | LD 50 | 321mg/kg   |
| Rat   | Intraperitoneal | LD 50 | 745mg/kg   |
| Mouse | Oral            | LD 50 | 2359mg/kg  |
| Mouse | Intravenous     | LD 50 | 820mg/kg   |

#### Benzyl Alcohol

|     |                 |      |            |
|-----|-----------------|------|------------|
| Rat | Oral            | LD50 | 1230 mg/kg |
| Rat | Para-periosteal | LD50 | 53mg/kg    |
| Rat | Inhalation      | LC50 | >4.178mg/L |

#### Edetate disodium

|     |      |      |                 |
|-----|------|------|-----------------|
| Rat | Oral | LD50 | 2000-2200 mg/kg |
|-----|------|------|-----------------|

#### Sodium hydroxide

|       |    |      |          |
|-------|----|------|----------|
| Mouse | IP | LD50 | 40 mg/kg |
|-------|----|------|----------|

## SAFETY DATA SHEET

Material Name: Clindamycin phosphate injection, solution  
(Hospira, Inc.)  
Revision date: 24-Mar-2017

Page 8 of 11

Version: 1.0

### 11. TOXICOLOGICAL INFORMATION

#### HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Clindamycin Phosphate

Eye Irritation Rabbit Moderate  
Skin Irritation Rabbit Mild

##### Benzyl Alcohol

Eye Irritation Rabbit Severe  
Skin Irritation Rabbit Minimal  
Skin Irritation Guinea Pig Moderate

##### Sodium hydroxide

Eye Irritation Rabbit Severe  
Skin Irritation Rabbit Severe

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### Clindamycin Phosphate

6 Month(s) Rat Oral 600 mg/kg/day NOAEL No effects at maximum dose  
6 Month(s) Dog Oral 600 mg/kg/day NOAEL Gastrointestinal system

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

##### Clindamycin Phosphate

Prenatal & Postnatal Development Rat Subcutaneous 250 mg/kg NOAEL Not teratogenic  
Prenatal & Postnatal Development Rat Oral 300 mg/kg/day NOAEL Not Teratogenic  
Prenatal & Postnatal Development Mouse Oral 600 mg/kg/day NOAEL Not Teratogenic  
Prenatal & Postnatal Development Rabbit Subcutaneous 5 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity  
Reproductive & Fertility Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### Clindamycin Phosphate

Bacterial Mutagenicity (Ames) *Salmonella* Negative  
*In Vitro* Micronucleus Rat Negative

##### HYDROCHLORIC ACID

Bacterial Mutagenicity (Ames) *Salmonella* Negative  
*In Vivo* Micronucleus Rat Negative

#### Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

#### HYDROCHLORIC ACID

##### IARC:

Group 3 (Not Classifiable)



## SAFETY DATA SHEET

Material Name: Clindamycin phosphate injection, solution  
(Hospira, Inc.)  
Revision date: 24-Mar-2017

Page 9 of 11

Version: 1.0

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

**Toxicity:**

**Aquatic Toxicity: (Species, Method, End Point, Duration, Result)**

**Benzyl Alcohol**

|   |      |      |          |          |
|---|------|------|----------|----------|
| <i>Pimephales promelas</i> (Fathead Minnow)         | EPA  | LC50 | 96 Hours | 460 mg/L |
| <i>Daphnia magna</i> (Water Flea)                   | OECD | EC50 | 48 Hours | 230 mg/L |
| <i>Pseudokirchneriella subcapitata</i> (Green Alga) | OECD | EC50 | 72 Hours | 500 mg/L |

**Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)**

**Benzyl Alcohol**

*Daphnia magna* (Water Flea) OECD 21 Day(s) EC50 66 mg/L Reproduction

**Persistence and Degradability:**

**Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)**

**Benzyl Alcohol**

OECD Activated sludge Ready 92% After 14 Day(s) Ready

**Bio-accumulative Potential:** No data available

**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:**

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

**SAFETY DATA SHEET**

Material Name: Clindamycin phosphate injection, solution  
 (Hospira, Inc.)  
 Revision date: 24-Mar-2017

Page 10 of 11

Version: 1.0

**15. REGULATORY INFORMATION**

**Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture**

**Water for Injection**

|   |            |
|---|------------|
| CERCLA/SARA 313 Emission reporting                              | Not Listed |
| California Proposition 65                                       | Not Listed |
| Inventory - United States TSCA - Sect. 8(b)                     | Present    |
| Australia (AICS):   | Present    |
| REACH - Annex IV - Exemptions from the obligations of Register: | Present    |
| EU EINECS/ELINCS List   | 231-791-2  |

**Clindamycin Phosphate**

|                                    |            |
|------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65          | Not Listed |
| EU EINECS/ELINCS List              | 246-433-0  |

**Benzyl Alcohol**

|   |            |
|---|------------|
| CERCLA/SARA 313 Emission reporting          | Not Listed |
| California Proposition 65                   | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present    |
| Australia (AICS):                           | Present    |
| EU EINECS/ELINCS List                       | 202-859-9  |

**HYDROCHLORIC ACID**

|  |            |
|--|------------|
| CERCLA/SARA 313 Emission reporting                                 | 1.0 %      |
| CERCLA/SARA Hazardous Substances and their Reportable Quantities:  | 5000 lb    |
|  | 2270 kg    |
| CERCLA/SARA - Section 302 Extremely Hazardous TPQs                 | 500 lb     |
| CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs | 5000 lb    |
| California Proposition 65  | Not Listed |
| Inventory - United States TSCA - Sect. 8(b)                        | Present    |
| Australia (AICS):  | Present    |
| Standard for the Uniform Scheduling for Drugs and Poisons:         | Schedule 5 |
|  | Schedule 6 |
| EU EINECS/ELINCS List  | 231-595-7  |

**Sodium hydroxide**

|   |            |
|---|------------|
| CERCLA/SARA 313 Emission reporting                                | Not Listed |
| CERCLA/SARA Hazardous Substances and their Reportable Quantities: | 1000 lb    |
|   | 454 kg     |
| California Proposition 65   | Not Listed |
| Inventory - United States TSCA - Sect. 8(b)                       | Present    |
| Australia (AICS):   | Present    |
| Standard for the Uniform Scheduling for Drugs and Poisons:        | Schedule 5 |
|   | Schedule 6 |
| EU EINECS/ELINCS List   | 215-185-5  |

## SAFETY DATA SHEET

Material Name: Clindamycin phosphate injection, solution  
(Hospira, Inc.)  
Revision date: 24-Mar-2017

Page 11 of 11

Version: 1.0

### 15. REGULATORY INFORMATION

### 16. OTHER INFORMATION

#### Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed  
Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled  
Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation  
Skin corrosion/irritation-Cat.3; H316 - Causes mild skin irritation  
Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction  
Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage  
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

**Data Sources:** Publicly available toxicity information. Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

**Reasons for Revision:** New data sheet.

**Revision date:** 24-Mar-2017

**Prepared by:** Product Stewardship Hazard Communication  
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**